

Q1FY22 result review  
and earnings revisionSpeciality  
Chemicals

Target price: Rs762

## Earnings revision

(%)	FY22E	FY23E
Revenue	↓ 0.0	↓ 0.0
EBITDA	↓ 1.2	↓ 1.2
PAT	↓ 1.5	↓ 0.6

## Target price revision


Rs762 from Rs708

## Shareholding pattern

	Dec '20	Mar '21	Jun '21
Promoters	40.0	40.0	39.6
Institutional investors	16.1	18.4	18.1
MFs and other	5.0	7.3	7.5
Banks/FIs	1.5	1.4	1.4
FII	9.6	9.6	9.2
Others	43.9	41.6	41.3

Source: NSE

## Price chart



## Research Analysts:

Sanjesh Jain

sanjesh.jain@icicisecurities.com  
+91 22 6637 7153

## INDIA

## Sudarshan Chemical Industries

ADD

Maintained

**Rs698**

## Margin pressure from cost inflation

Sudarshan Chemical Industries' (SCIL) Q1FY22 EBITDA was lower than expected at Rs620mn, down 29% QoQ / up 8% YoY, and was hit due to lockdown in India (revenues down 26% QoQ) and rise in operating costs. Gross profit margin expansion of 430bps QoQ was result of low-cost inventory, and SCIL sees near-term margins to remain volatile due to higher raw material prices. Further, higher coal and freight costs have put margins under pressure. Q2FY22 revenues will be adversely impacted due to Mahad plant closure for two weeks. Company sees new plant commissioning and product launches to help grow revenues from H2FY22 onward. We marginally cut our EPS estimates by ~1% each year for FY22E and FY23E, but increase the target price to Rs762 (earlier: Rs708), implying 26x FY23E P/E (earlier: 24x). Maintain ADD.

- ▶ **India pigment revenues fell 26% QoQ.** SCIL's revenues from the pigment segment grew 33% YoY to Rs4.5bn on low base, but dipped 15% QoQ due to lower revenues in India market (down 26% QoQ to Rs2bn), due to lockdown. Categories worst affected in India are: plastics, coatings and inks. International revenues were steady at Rs2.5bn, up 13% YoY (down only 3.8% QoQ). Specialty pigment revenues shrunk 12% QoQ to Rs3.2bn, while non-specialty revenues fell 21% to Rs1.4bn. Q2FY22 will be impacted due to Mahad plant closure for two weeks on heavy rainfall, but H2FY22 should benefit from new product launches and commercialisation of new facilities. Company also has three new product category launches planned (pushed from Sep'21 to Q3/Q4FY22) with 10-15 products in each category. New yellow pigment continues to grow, but SCIL expects inflection point in revenues only in Q3FY23.
- ▶ **Margins to remain volatile in near term.** SCIL's gross profit margin rose 430bps QoQ to 46.4% benefiting from low-cost inventories. It expects price rise in multiple intermediates, which will keep margins under pressure in the near term. Margins were also hit due to rise in fuel and freight costs. Employee costs too witnessed high inflation resulting from two increments and investment in sales personnel for the international market. Subsidiary RIECO incurred EBIT loss of Rs42mn (vs Rs34mn profit in Q4FY21) on lower revenues due to lockdown-driven difficulty in execution. Company sees RIECO margins normalising in FY22. We expect SCIL's EBITDA margins to improve on the back of higher revenues, stabilisation of gross profit margins, and better product mix.
- ▶ **Capex continues.** Company is in the process of executing capex of Rs380mn, which was a spillover from FY21; this should help commercialise Rs3.07bn of investments; of which Rs1.2bn will come in Q3FY22, and remaining in Q4FY22. SCIL is also in the process of incurring capex of Rs1.35bn on infrastructure announced in FY21.

Market Cap	Rs48.3bn/US\$651mn
Reuters/Bloomberg	SDCH.BO/SCHI IN
Shares Outstanding (mn)	69.2
52-week Range (Rs)	770/408
Free Float (%)	60.4
FII (%)	9.2
Daily Volume (US\$'000)	3,710
Absolute Return 3m (%)	11.2
Absolute Return 12m (%)	56.8
Sensex Return 3m (%)	11.2
Sensex Return 12m (%)	44.6

Year to March	FY20	FY21	FY22E	FY23E
Revenue (Rs mn)	17.1	18.6	22.1	24.5
Rec. Net Income (Rs mn)	1.4	1.4	1.8	2.0
EPS (Rs)	19.0	20.4	26.4	29.3
% Chg YoY	26.5	7.3	29.6	10.9
P/E (x)	33.4	34.2	26.4	23.8
CEPS (Rs)	31.5	32.9	41.0	46.1
EV/E (x)	21.6	18.8	14.3	12.9
Dividend Yield (%)	1.8	1.7	0.9	0.9
RoCE (%) (pre-tax)	17.0	16.4	18.7	18.2
RoE (%)	24.7	21.0	22.5	21.1

**Table 1: Sudarshan Chemical (consolidated) financials**

(Rs mn)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	QoQ (%)	YoY (%)
Revenue	3,523	4,289	5,064	5,765	4,739	(17.8)	42.6
COGS	1,972	2,394	2,897	3,342	2,542	(23.9)	31.8
<b>Gross profit</b>	<b>1,551</b>	<b>1,895</b>	<b>2,166</b>	<b>2,424</b>	<b>2,197</b>	<b>(9.3)</b>	<b>57.6</b>
GPM (%)	44.0	44.2	42.8	42.0	46.4		
Employee cost	368	365	429	395	441	11.6	73.6
% of revenue	10.4	8.5	8.5	6.8	9.3		
Other expenses	653	853	942	1,154	1,137	(1.5)	100.8
% of revenue	18.5	19.9	18.6	20.0	24.0		
<b>Total expenses</b>	<b>1,021</b>	<b>1,218</b>	<b>1,370</b>	<b>1,549</b>	<b>1,577</b>	<b>1.8</b>	<b>92.4</b>
<b>EBITDA</b>	<b>530</b>	<b>677</b>	<b>796</b>	<b>875</b>	<b>620</b>	<b>(29.1)</b>	<b>7.9</b>
EBITDA (%)	15.0	15.8	15.7	15.2	13.1		
Depreciation	216	219	217	214	210	(1.7)	(1.7)
<b>EBIT</b>	<b>314</b>	<b>458</b>	<b>580</b>	<b>661</b>	<b>410</b>	<b>(38.0)</b>	<b>13.6</b>
Other income	3	18	26	23	7	(70.1)	217.7
Finance cost	39	51	46	42	47		
<b>PBT</b>	<b>278</b>	<b>425</b>	<b>559</b>	<b>642</b>	<b>370</b>	<b>(42.4)</b>	<b>12.3</b>
Tax	96	121	168	108	108	(0.0)	14.8
ETR (%)	34.5	28.6	30.0	16.8	29.2		
Exceptional item	-	-	-	-	-		
<b>Net profit</b>	<b>182</b>	<b>303</b>	<b>392</b>	<b>534</b>	<b>262</b>	<b>(51.0)</b>	<b>43.9</b>
Net profit (%)	5.2	7.1	7.7	9.3	5.5		
<b>EPS (Rs)</b>	<b>2.6</b>	<b>4.4</b>	<b>5.7</b>	<b>7.7</b>	<b>3.8</b>	<b>(51.0)</b>	<b>43.9</b>

Source: Company data, I-Sec research

**Table 2: Sudarshan Chemical (consolidated) segmental**

Rs mn	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	QoQ (%)	YoY (%)
<b>Segment revenue</b>							
Pigments	3,413	4,020	4,771	5,326	4,532	(14.9)	32.8
Others	110	269	293	440	207	(52.8)	89.3
<i>Intersegment elimination</i>							
<b>Total revenue</b>	<b>3,523</b>	<b>4,289</b>	<b>5,064</b>	<b>5,765</b>	<b>4,739</b>	<b>(17.8)</b>	<b>34.5</b>
<b>Revenue mix (%)</b>							
Pigments	96.9	93.7	94.2	92.4	95.6		
Others	3.1	6.3	5.8	7.6	4.4		

Source: Company data, I-Sec research

**Table 3: Sudarshan Chemical (consolidated) segmental**

Rs mn	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	QoQ (%)
<b>Pigment</b>						
Specialty	2,400	3,290	3,630	3,180		(12.4)
Non specialty	1,010	1,480	1,700	1,350		(20.6)
<b>Total</b>	<b>3,410</b>	<b>4,770</b>	<b>5,330</b>	<b>4,530</b>		<b>(15.0)</b>
<b>Mix (%)</b>						
Specialty	70.4	69.0	68.1	70.2		
Non specialty	29.6	31.0	31.9	29.8		
<b>Pigment</b>						
Domestic	1,200	2,610	2,730	2,030		(25.6)
Export	2,210	2,160	2,600	2,500		(3.8)
<b>Total</b>	<b>3,410</b>	<b>4,770</b>	<b>5,330</b>	<b>4,530</b>		<b>(15.0)</b>
<b>Mix (%)</b>						
Domestic	35.2	54.7	51.2	44.8		
Export	64.8	45.3	48.8	55.2		

Source: Company data, I-Sec research

**Table 4: Sudarshan Chemicals (standalone)**

Rs mn	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	QoQ (%)	YoY (%)
Revenue	3,323	3,951	4,616	5,195	4,347	(16.3)	30.8
COGS	1,928	2,308	2,702	3,138	2,441	(22.2)	26.6
<b>Gross profit</b>	<b>1,394</b>	<b>1,643</b>	<b>1,914</b>	<b>2,058</b>	<b>1,906</b>	<b>(7.4)</b>	<b>36.7</b>
GPM (%)	42.0	41.6	41.5	39.6	43.8		
Employee cost	254	243	306	284	329	15.9	29.5
% of revenue	7.6	6.2	6.6	5.5	7.6		
Other expenses	566	757	847	1,091	1,042	(4.5)	84.1
% of revenue	17.0	19.2	18.3	21.0	24.0		
<b>Total expenses</b>	<b>820</b>	<b>1,000</b>	<b>1,153</b>	<b>1,375</b>	<b>1,371</b>	<b>(0.3)</b>	<b>67.2</b>
<b>EBITDA</b>	<b>575</b>	<b>642</b>	<b>761</b>	<b>683</b>	<b>535</b>	<b>(21.6)</b>	<b>(6.8)</b>
EBITDA (%)	17.3	16.3	16.5	13.1	12.3		
Depreciation	214	215	213	210	205	(2.4)	(4.3)
<b>EBIT</b>	<b>361</b>	<b>428</b>	<b>548</b>	<b>473</b>	<b>331</b>	<b>(30.2)</b>	<b>(8.3)</b>
Other income	2	5	25	27	7	(73.7)	218.2
Finance cost	34	47	43	41	43	5.2	26.5
<b>PBT</b>	<b>329</b>	<b>386</b>	<b>531</b>	<b>459</b>	<b>295</b>	<b>(35.8)</b>	<b>(10.4)</b>
Tax	94	108	184	64	74	16.4	(20.7)
ETR (%)	28.5	28.0	34.7	13.9	25.3		
Exceptional item	-	-	107	-	-		
<b>Net profit</b>	<b>235</b>	<b>278</b>	<b>347</b>	<b>395</b>	<b>220</b>	<b>(44.3)</b>	<b>(6.3)</b>
Net profit (%)	7.1	7.0	7.5	7.6	5.1		

Source: Company data, I-Sec research

**Table 5: Sudarshan Chemicals (consolidated minus standalone)**

Rs mn	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	QoQ (%)	YoY (%)
Revenue	200	338	448	570	392	(31.2)	95.9
COGS	44	85	196	204	101	(50.5)	131.6
<b>Gross profit</b>	<b>157</b>	<b>253</b>	<b>252</b>	<b>366</b>	<b>291</b>	<b>(20.4)</b>	<b>86.0</b>
GPM (%)	78.2	74.7	56.3	64.2	74.3		
Employee cost	114	122	122	111	112	0.7	(1.9)
% of revenue	57.0	36.0	27.3	19.5	28.5		
Other expenses	87	96	95	63	95	49.7	8.3
% of revenue	43.6	28.5	21.2	11.1	24.1		
<b>Total expenses</b>	<b>201</b>	<b>218</b>	<b>217</b>	<b>174</b>	<b>207</b>	<b>18.5</b>	<b>2.5</b>
<b>EBITDA</b>	<b>(45)</b>	<b>34</b>	<b>35</b>	<b>192</b>	<b>85</b>	<b>(55.8)</b>	<b>(289.0)</b>
EBITDA (%)	(22.4)	10.2	7.8	33.6	21.6		
Depreciation	2	4	3	4	6	32.9	
<b>EBIT</b>	<b>(47)</b>	<b>30</b>	<b>32</b>	<b>188</b>	<b>79</b>	<b>(57.7)</b>	<b>(269.4)</b>
Other income	1	13	0	(3)	(0)	(99.7)	(101.2)
Finance cost	5	5	3	2	4		
<b>PBT</b>	<b>(51)</b>	<b>39</b>	<b>29</b>	<b>183</b>	<b>75</b>	<b>(59.0)</b>	<b>(246.4)</b>
Tax	2	13	(16)	44	33	(24.0)	1,549.0
ETR (%)	(4.0)	34.1	(57.3)	24.0	44.5		
Minority interest				(107)			
<b>Net profit</b>	<b>(53)</b>	<b>25</b>	<b>45</b>	<b>32</b>	<b>42</b>	<b>30.6</b>	<b>(178.2)</b>
Net profit (%)	(26.5)	7.5	10.0	5.6	10.6		

Source: Company data, I-Sec research

**Table 6: Earnings revision**

Consolidated	Revised		Earlier		% change	
	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
<b>Financial</b>						
Revenue	22,058	24,518	22,058	24,518	(0.0)	(0.0)
EBITDA	3,735	4,180	3,778	4,229	(1.2)	(1.2)
EBITDA margin (%)	16.9	17.0	17.1	17.2		
PAT	1,830	2,028	1,858	2,041	(1.5)	(0.6)
EPS (Rs)	26.4	29.3	26.8	29.5	(1.5)	(0.6)

Source: Company data, I-Sec research

## Financial summary

**Table 7: Profit & Loss statement**

(Rs mn, year ending March 31)

	FY20	FY21	FY22E	FY23E
<b>Operating Income (Sales)</b>	<b>17,082</b>	<b>18,641</b>	<b>22,058</b>	<b>24,518</b>
<b>Operating Expenses</b>	<b>14,619</b>	<b>15,763</b>	<b>18,323</b>	<b>20,338</b>
<b>EBITDA</b>	<b>2,463</b>	<b>2,878</b>	<b>3,735</b>	<b>4,180</b>
% margins	14.4	15.4	16.9	17.0
Depreciation & Amortisation	735	865	1,012	1,165
Net Interest	142	179	360	389
Other Income	47	70	73	76
<b>Recurring PBT</b>	<b>1,633</b>	<b>1,904</b>	<b>2,436</b>	<b>2,702</b>
Add: Extraordinaries	166	-	-	-
Less: Taxes	353	493	606	673
<b>Net Income (Reported)</b>	<b>1,445</b>	<b>1,411</b>	<b>1,830</b>	<b>2,028</b>
<b>Recurring Net Income</b>	<b>1,445</b>	<b>1,411</b>	<b>1,830</b>	<b>2,028</b>

Source: Company data, I-Sec research

**Table 8: Balance sheet**

(Rs mn, year ending March 31)

	FY20	FY21	FY22E	FY23E
<b>Assets</b>				
Total Current Assets	8,637	10,316	13,511	15,245
of which cash & cash equiv.	156	238	1,428	1,668
Total Current Liabilities & Provisions	7,344	8,593	10,162	11,462
<b>Net Current Assets</b>	<b>1,293</b>	<b>1,722</b>	<b>3,349</b>	<b>3,784</b>
Investments	9	13	13	13
of which				
Strategic/Group	-	-	-	-
Other Marketable	-	-	-	-
<b>Net Fixed Assets</b>	<b>6,751</b>	<b>8,932</b>	<b>8,729</b>	<b>9,864</b>
Other non-current	900	773	836	890
<b>Total Assets</b>	<b>8,952</b>	<b>11,440</b>	<b>12,927</b>	<b>14,551</b>
<b>Liabilities</b>				
Borrowings	2,250	3,081	3,081	3,081
Deferred tax liability	501	529	529	529
Long term liabilities and provisions	193	395	467	520
Equity Share Capital	138	138	138	138
Face Value per share (Rs)	2	2	2	2
Reserves & Surplus	5,869	7,297	8,712	10,283
<b>Net Worth</b>	<b>6,008</b>	<b>7,436</b>	<b>8,850</b>	<b>10,422</b>
<b>Total Liabilities</b>	<b>8,952</b>	<b>11,440</b>	<b>12,928</b>	<b>14,551</b>

Source: Company data, I-Sec research

**Table 9: Quarterly trend**

(Rs mn, year ending March 31)

	Sep-20	Dec-20	Mar-21	Jun-21
Net sales	4,289	5,064	5,765	4,739
% growth (YoY)	1.0	19.6	28.4	34.5
EBITDA	677	796	875	620
Margin (%)	15.8	15.7	15.2	13.1
Other income	18	26	23	7
Add: Extra ordinaries	-	-	-	-
Net profit	303	392	534	262

Source: Company data

**Table 10: Cashflow statement**

(Rs mn, year ending March 31)

	FY20	FY21	FY22E	FY23E
<b>Operating Cashflow</b>	<b>2,123</b>	<b>2,559</b>	<b>3,128</b>	<b>3,507</b>
Working Capital Changes	508	(907)	(927)	(697)
Capital Commitments	(2,554)	(2,696)	(810)	(2,300)
<b>Free Cashflow</b>	<b>78</b>	<b>(1,044)</b>	<b>1,392</b>	<b>510</b>
<b>Cashflow from Investing Activities</b>	<b>355</b>	<b>37</b>	<b>73</b>	<b>76</b>
Issue of Share Capital	-	-	-	-
Inc (Dec) in Borrowings	751	1,269	500	500
Dividend paid & Others	(1,144)	(184)	(775)	(846)
<b>Chg. in Cash &amp; Bank balance</b>	<b>40</b>	<b>78</b>	<b>1,189</b>	<b>240</b>

Source: Company data, I-Sec research

**Table 11: Key ratios**

(Year ending March 31)

	FY20	FY21	FY22E	FY23E
<b>Per Share Data (in Rs.)</b>				
Reported EPS	20.9	20.4	26.4	29.3
Dividend per share (DPS)	12.3	12.0	6.0	6.6
Book Value per share (BV)	86.8	107.4	127.8	150.5
<b>Growth Ratios (%)</b>				
Operating Income	15.7	9.1	18.3	11.2
EBITDA	16.8	16.8	29.8	11.9
Recurring Net Income	3.4	(2.3)	29.6	10.9
Diluted Recurring EPS	26.5	7.3	29.6	10.9
Diluted Recurring CEPS	6.5	4.4	24.8	12.4
<b>Valuation Ratios</b>				
P/E	33.4	34.2	26.4	23.8
P/CEPS	22.2	21.2	17.0	15.1
P/BV	8.0	6.5	5.5	4.6
EV / EBITDA	21.6	18.8	14.3	12.9
EV / Operating Income	3.1	2.9	2.4	2.2
EV / Operating FCF	682.6	(51.9)	38.5	105.5
<b>Operating Ratios</b>				
Other Income / PBT (%)	2.9	3.7	3.0	2.8
Effective Tax Rate (%)	21.7	25.9	24.9	24.9
NWC / Total Assets (%)	14.4	15.1	25.9	26.0
Inventory Turnover (days)	87.7	80.6	79.7	79.6
Receivables (days)	77.8	94.9	97.4	99.1
Payables (days)	79.4	86.4	87.8	89.0
Net Debt/EBITDA Ratio (x)	2.0	2.1	1.4	1.3
Capex % of sales	14.9	14.5	10.0	9.4
<b>Return/Profitability Ratio (%)</b>				
Recurring Net Income Margins	8.5	7.6	8.3	8.3
RoCE (pre-tax)	17.0	16.4	18.7	18.2
RoIC	13.5	12.3	14.9	15.1
RoNW	24.7	21.0	22.5	21.1
Dividend Yield	1.8	1.7	0.9	0.9
Gross Margins	42.9	43.1	43.7	43.6
EBITDA Margins	14.4	15.4	16.9	17.0

Source: Company data, I-Sec research

*This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet\_babbar@icicisecuritiesinc.com, Rishi\_agrawal@icicisecuritiesinc.com.*

*"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."*

*New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)  
BUY: >15 return: ADD: 5 to 15 return: HOLD: Negative 5 to Positive 5 return: REDUCE: Negative 5 to Negative 15 return: SELL: < negative 15 return*

#### **ANALYST CERTIFICATION**

I/We, Sanjesh Jain, PGDM; Sameer Pardikar, MBA authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### **Terms & conditions and other disclosures:**

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.